NeuroMetrix (NURO) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroMetrix Reports Q4 and Full Year 2016 Financial Results
January 26, 2017 7:00 AM EST2016 revenue $12.0M up 65% year-on-year; Q4 revenue $3.7M up 36% Quell device shipments of 14.3K and electrode reorders of 20K represent new quarterly highs
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and business highlights for the quarter and year ended December 31, 2016.
The Company develops and markets novel therapies, based on bioelectrical and digital medicine, for chronic conditions. The Companys primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain that was launched in Q2... More
